EGFR and cancer: Indeed, known EGFR inhibitors that preferentially recognize the active kinase conformation, as promoted by the ΔELREA deletion, exert a more dramatic effect–reducing cell survival in cancer cell models–in comparison to conformationally malleable wild-type EGFR.